After mTOR inhibitors: What is next?

被引:0
|
作者
Turner, N. [1 ,2 ]
机构
[1] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S39 / S39
页数:1
相关论文
共 50 条
  • [1] Bivalent mTOR inhibitors — the next generation
    Alexandra Flemming
    Nature Reviews Drug Discovery, 2016, 15 (7) : 455 - 455
  • [2] Virus proteinase inhibitors - What next after HIV?
    Mills, JS
    ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1996, 7 (06): : 281 - 293
  • [3] Virus proteinase inhibitors - what next after HIV?
    Mills, J. S.
    Antiviral Chemistry & Chemotherapy, 7 (06):
  • [4] The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches
    Ihlamur, Murat
    Akgul, Busra
    Zengin, Yagmur
    Korkut, Senay Vural
    Kelleci, Kubra
    Abamor, Emrah Sefik
    CURRENT MOLECULAR MEDICINE, 2024, 24 (04) : 478 - 494
  • [5] What’s next for PARP inhibitors?
    Simon Makin
    Nature, 2021, 600 (7889) : S36 - S38
  • [6] Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
    Ashworth, Alan
    Lord, Christopher J.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (09) : 564 - 576
  • [7] Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
    Alan Ashworth
    Christopher J. Lord
    Nature Reviews Clinical Oncology, 2018, 15 : 564 - 576
  • [8] The next-generation KRAS inhibitors...What comes after sotorasib and adagrasib?
    Oya, Yuko
    Imaizumi, Kazuyoshi
    Mitsudomi, Tetsuya
    LUNG CANCER, 2024, 194
  • [9] mTOR inhibitors (mTOR-I) and proteinuria after lung transplantation
    Ussetti, P.
    Carreno, M. C.
    Garcia-Gallo, C.
    Laporta, R.
    Mora, G.
    Garcia-Fadul, C.
    Sanchez, B.
    Ferreiro, M. J.
    Varela, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2008, 27 (02): : S75 - S76
  • [10] AFTER APOLLO WHAT NEXT
    CLEAVER, AV
    ASTRONAUTICS & AERONAUTICS, 1967, 5 (05): : 76 - &